Unveiling 10 Analyst Insights On Integra Lifesciences
Unveiling 10 Analyst Insights On Integra Lifesciences
揭示英特格拉生命科學的10個分析師見解
A comprehensive...In the last three months, 10 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有10位分析師發佈了對Integra Lifesciences（納斯達克：IART）的評級，提供了從看好到看淡的多樣化觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Analysts have recently evaluated Integra Lifesciences and provided 12-month price targets. The average target is $25.1, accompanied by a high estimate of $35.00 and a low estimate of $16.00. Experiencing a 7.41% decline, the current average is now lower than the previous average price target of $27.11.
分析師最近對英特格拉生命科學進行了評估，並提供了12個月的價格目標。平均目標價爲25.1美元，最高估值爲35.00美元，最低估值爲16.00美元。當前平均價格目標下降了7.41%，目前的平均價格比之前的27.11美元的目標價格更低。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
A comprehensive...
最近...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。